Moderna COVID Vaccine Is A Close Second Behind Pfizer

With Pfizer vaccines already underway across the U.S., the Moderna vaccine is following close behind; nearing readiness for FDA authorization. 

Hundreds of healthcare workers are receiving the Pfizer vaccine across the state of California. 

Moderna has said its coronavirus vaccine candidate has an efficacy rate of about 94%, based on data from clinical trials.

In the formal report, it states that the Moderna vaccine is believed to be effective: Based on the totality of scientific evidence available, including data from adequate and wellcontrolled trials, if available, it is reasonable to believe that the product may be effective to prevent, diagnose, or treat such serious or life-threatening disease or condition that can be caused by SARS-CoV-2, or to mitigate a serious or life-threatening disease or condition caused by an FDA-regulated product used to diagnose, treat, or prevent a disease or condition caused by SARS-CoV-2.

How would the vaccine be given?  The proposed dosing regimen is 2 doses, 100 μg each, administered 1 month apart.

Because Moderna is seeking authorization for people who are at least 18 years old, some analysts expect a unanimous vote in favor of the FDA authorizing mRNA-1273. “This should not be an issue for Moderna given the trial and EUA request,” Raymond James analyst Steven Seedhouse told investors on Wednesday, according to MarketWatch.

Learn more about the Moderna vaccine here:

More From LATF USA

Scroll to Top